Cargando…

2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program

BACKGROUND: Nonsusceptibility of Proteus mirabilis to imipenem allows this pathogen evade surveillance for carbapenemases. Metallo-beta-lactamases of the VIM family are widespread among Enterobacterales in Europe. We identified an outbreak of P. mirabilis carrying 2 VIM enzymes among elderly patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Deshpande, Lalitagauri M, Burián, Katalin, Csányi, Ilona Dóczi, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752648/
http://dx.doi.org/10.1093/ofid/ofac492.1658
_version_ 1784850779149959168
author Deshpande, Lalitagauri M
Burián, Katalin
Csányi, Ilona Dóczi
Castanheira, Mariana
author_facet Deshpande, Lalitagauri M
Burián, Katalin
Csányi, Ilona Dóczi
Castanheira, Mariana
author_sort Deshpande, Lalitagauri M
collection PubMed
description BACKGROUND: Nonsusceptibility of Proteus mirabilis to imipenem allows this pathogen evade surveillance for carbapenemases. Metallo-beta-lactamases of the VIM family are widespread among Enterobacterales in Europe. We identified an outbreak of P. mirabilis carrying 2 VIM enzymes among elderly patients from a medical center in Hungary. METHODS: A total of 16 P. mirabilis isolates were received from Hungary during 2020 as part of the SENTRY Antimicrobial Surveillance Program. Isolates were susceptibility tested by the CLSI reference broth microdilution method. Carbapenem-nonsusceptible isolates were submitted to whole genome sequencing, screened for resistance mechanisms, and evaluated for core genome multi-locus sequence typing (cgMLST). RESULTS: Among the 16 P. mirabilis isolates from Hungary, 5 carbapenem-nonsusceptible, multidrug-resistant isolates (3 from urinary tract infections and 1 each from bloodstream infection and pneumonia) were identified from patients 66-92 years old. Four of these 5 isolates were listed as community acquired. All isolates were resistant to ceftriaxone (MIC, > 8 mg/L), cefepime (16- > 32), imipenem ( > 8), gentamicin ( > 16), levofloxacin (16- > 32), nitrofurantoin ( > 64), trimethoprim/sulfamethoxazole ( > 4), and plazomicin ( > 128), but susceptible to meropenem (0.25-0.5) and ertapenem (0.03-0.25). Isolates carried bla(VIM-4) and bla(VIM-75) on a class 1 integron within IS26 and separated by aac(6’)-IIc. IS26 was located on a compound plasmid carrying other resistance-encoding genes, including armA. The integron structure is identical to the bla(VIM-4) and bla(VIM-1)-carrying integron described from a Vibrio cholerae isolated from a seagull in France in 2015 (KR262557). bla(VIM-75) is a single amino acid variant (Q60R) of bla(VIM-1). All isolates carried mutations in the QRDR (gyrA_S83I, parC_S84I). Based on cgMLST analysis, these 5 P. mirabilis isolates were highly similar, with only 7-19 SNPs detected. CONCLUSION: The outbreak of multidrug-resistant P. mirabilis isolates carrying bla(VIM-4) and bla(VIM-75) in a Hungarian medical center is a cause of concern. Surveillance should be performed to understand the spread of and treatment options for infections caused by carbapenem-nonsusceptible P. mirabilis. DISCLOSURES: Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Pfizer: Grant/Research Support Katalin Burián, MD, JMI Laboratories: Grant/Research Support Ilona Dóczi Csányi, MD, JMI Laboratories: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support.
format Online
Article
Text
id pubmed-9752648
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97526482022-12-16 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program Deshpande, Lalitagauri M Burián, Katalin Csányi, Ilona Dóczi Castanheira, Mariana Open Forum Infect Dis Abstracts BACKGROUND: Nonsusceptibility of Proteus mirabilis to imipenem allows this pathogen evade surveillance for carbapenemases. Metallo-beta-lactamases of the VIM family are widespread among Enterobacterales in Europe. We identified an outbreak of P. mirabilis carrying 2 VIM enzymes among elderly patients from a medical center in Hungary. METHODS: A total of 16 P. mirabilis isolates were received from Hungary during 2020 as part of the SENTRY Antimicrobial Surveillance Program. Isolates were susceptibility tested by the CLSI reference broth microdilution method. Carbapenem-nonsusceptible isolates were submitted to whole genome sequencing, screened for resistance mechanisms, and evaluated for core genome multi-locus sequence typing (cgMLST). RESULTS: Among the 16 P. mirabilis isolates from Hungary, 5 carbapenem-nonsusceptible, multidrug-resistant isolates (3 from urinary tract infections and 1 each from bloodstream infection and pneumonia) were identified from patients 66-92 years old. Four of these 5 isolates were listed as community acquired. All isolates were resistant to ceftriaxone (MIC, > 8 mg/L), cefepime (16- > 32), imipenem ( > 8), gentamicin ( > 16), levofloxacin (16- > 32), nitrofurantoin ( > 64), trimethoprim/sulfamethoxazole ( > 4), and plazomicin ( > 128), but susceptible to meropenem (0.25-0.5) and ertapenem (0.03-0.25). Isolates carried bla(VIM-4) and bla(VIM-75) on a class 1 integron within IS26 and separated by aac(6’)-IIc. IS26 was located on a compound plasmid carrying other resistance-encoding genes, including armA. The integron structure is identical to the bla(VIM-4) and bla(VIM-1)-carrying integron described from a Vibrio cholerae isolated from a seagull in France in 2015 (KR262557). bla(VIM-75) is a single amino acid variant (Q60R) of bla(VIM-1). All isolates carried mutations in the QRDR (gyrA_S83I, parC_S84I). Based on cgMLST analysis, these 5 P. mirabilis isolates were highly similar, with only 7-19 SNPs detected. CONCLUSION: The outbreak of multidrug-resistant P. mirabilis isolates carrying bla(VIM-4) and bla(VIM-75) in a Hungarian medical center is a cause of concern. Surveillance should be performed to understand the spread of and treatment options for infections caused by carbapenem-nonsusceptible P. mirabilis. DISCLOSURES: Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Pfizer: Grant/Research Support Katalin Burián, MD, JMI Laboratories: Grant/Research Support Ilona Dóczi Csányi, MD, JMI Laboratories: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support. Oxford University Press 2022-12-15 /pmc/articles/PMC9752648/ http://dx.doi.org/10.1093/ofid/ofac492.1658 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Deshpande, Lalitagauri M
Burián, Katalin
Csányi, Ilona Dóczi
Castanheira, Mariana
2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title_full 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title_fullStr 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title_full_unstemmed 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title_short 2036. Dual VIM-producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
title_sort 2036. dual vim-producing proteus mirabilis, including a novel vim-75, among elderly patients in a medical center from hungary: report from the 2020 sentry antimicrobial surveillance program
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752648/
http://dx.doi.org/10.1093/ofid/ofac492.1658
work_keys_str_mv AT deshpandelalitagaurim 2036dualvimproducingproteusmirabilisincludinganovelvim75amongelderlypatientsinamedicalcenterfromhungaryreportfromthe2020sentryantimicrobialsurveillanceprogram
AT buriankatalin 2036dualvimproducingproteusmirabilisincludinganovelvim75amongelderlypatientsinamedicalcenterfromhungaryreportfromthe2020sentryantimicrobialsurveillanceprogram
AT csanyiilonadoczi 2036dualvimproducingproteusmirabilisincludinganovelvim75amongelderlypatientsinamedicalcenterfromhungaryreportfromthe2020sentryantimicrobialsurveillanceprogram
AT castanheiramariana 2036dualvimproducingproteusmirabilisincludinganovelvim75amongelderlypatientsinamedicalcenterfromhungaryreportfromthe2020sentryantimicrobialsurveillanceprogram